27452-17-1

Usage

Uses

1. Used in Pharmaceutical Industry:
6-BROMO-1,1,4,4-TETRAMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENE is used as a key intermediate compound for the synthesis of synthetic retinoid derivatives. These derivatives are known to induce stem cell differentiation, which is a crucial process in the development and regeneration of tissues and organs. The compound plays a significant role in the development of new drugs and therapies targeting various diseases and conditions.
2. Used in Chemical Research:
6-BROMO-1,1,4,4-TETRAMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENE is also used as a research compound in the field of organic chemistry. Its unique structure and properties make it an interesting subject for studying various chemical reactions and mechanisms, which can lead to the discovery of new compounds and applications.
3. Used in Material Science:
The compound may also find applications in the field of material science, where its unique properties can be utilized in the development of new materials with specific characteristics. These materials could have potential uses in various industries, such as electronics, automotive, and aerospace.

InChI:InChI=1/C14H19Br/c1-13(2)7-8-14(3,4)12-9-10(15)5-6-11(12)13/h5-6,9H,7-8H2,1-4H3

Upstream product

• 108-86-1 bromobenzene 
• 6223-78-5 2,5-dichloro-2,5-dimethyl hexane 
• 6683-46-1 1,1,4,4-Tetramethyl-1,2,3,4-tetrahydro-naphthalene 
• 92050-16-3 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylamine 
• 110-03-2 2,5-dimethyl-2,5-hexanediol 

Downstream Products

• 92654-79-0 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxaldehyde 
• 75078-91-0 (E)-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-(1-methyl-2-phenylethenyl)-naphthalene 
• 89410-65-1 (Z)-1,1,4,4-tetramethyl-6-(1-phenylprop-1-en-2-yl)-1,2,3,4-tetrahydronaphthalene 
• 188844-71-5 5,5,8,8-tetramethyl-N-(2-nitrophenyl)-5,6,7,8-tetrahydronaphthalen-2-amine 
• 259219-19-7 (4-methoxy-2-nitro-phenyl)-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-amine 
• 853998-14-8 4,4,5,5-tetramethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,2-dioxaborolane 
• 312738-49-1 (Z)-4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2-(trimethylsilyl)vinyl]benzyl alcohol 
• 169126-63-0 5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthylboronic Acid 
• 120081-57-4 N-ethyl 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl) hydroxy methyl] phenyl sulfonamide 
• 1416254-99-3 C₂₃H₂₉NO₂ 

Relevant academic research and scientific papers

Phosphine-Catalyzed Difunctionalization of β-Fluoroalkyl α,β-Enones: A Direct Approach to β-Amino α-Diazo Carbonyl Compounds

An efficient and practical phosphine-catalyzed vicinal difunctionalization of β-fluoroalkyl α,β-enones with TMSN3 has been developed. Using dppb as the catalyst, the reaction worked efficiently to yield various β-amino α-diazocarbonyl compounds in high yields (up to 94 %). This work marks the first efficient construction of α-diazocarbonyl compounds by phosphine catalysis. Meanwhile, the asymmetric variant induced by the nucleophilic bifunctional phosphine P4 led to various chiral fluoroalkylated β-amino α-diazocarbonyl compounds in high yields and enantioselectivity. NMR and ESI-MS studies support the existence of the key reaction intermediates. In contrast, β-azide carbonyl compounds would be furnished in good yields from β-fluoroalkylated β,β-disubstituted enones.

COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS

Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity. Also provided herein are processes for the preparation of compounds that have retinoid-like biological activity.

Design, synthesis and anticancer biological evaluation of novel 1,4-diaryl-1,2,3-triazole retinoid analogues of tamibarotene (AM80)

We report herein the design and synthesis via click chemistry of twelve novel triazole retinoid analogues of tamibarotene (AM80) and the evaluation of their anticancer activities against six cancer cell lines: HL60, K562, 786, HT29, MCF7 and PC3. Among the synthesized compounds, two were more potent than tamibarotene against solid tumor cells, and one of them had similar potency to tamibarotene against HL60 cells. The bioisosteric exchange between the amide group and the 1,2,3-triazole core in the retinoid agent tamibarotene (AM80) reported in this work is a valid strategy for the generation of useful compounds against cancer.

COMPOUNDS AND METHODS FOR INHIBITING CYP26 ENZYMES

Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.

aromatic compound having fused cyclic substituent in aromatic ring and organic light-emitting diode including the same

The present invention relates to a compound having a cyclic substituent fused with a cyclic ring and an organic light emitting diode including the same, and more particularly, to a compound for an organic light emitting diode represented by chemical formula A and an organic light emitting diode including the same. In chemical formula A, X is a substituent having structural formula X, Y is a substituent of structural formula Y1, n is an integer from 1 to 4, and structural formulas X and Y1 are the same as described in detailed description of the present invention.

EXPANSION OF RENEWABLE STEM CELL POPULATIONS

Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.

Benzocarbazoles dioxane derivatives, its preparation process and its use in medicine

The invention relates to a benzodioxane derivative, a preparation method thereof and application of the derivative in medicines. Specifically, the invention relates to a novel benzodioxane derivative shown as a formula (I), medial salt thereof or a medicine composition containing the derivative, and a preparation method of the derivative. The invention further relates to a use of the benzodioxane derivative and the medial salt thereof or the medicine composition containing the derivative in preparing therapeutic agent, especially GPR 40 agonist, and a drug for treating the diseases such as diabetes, metabolic disorders and the like, wherein each substituent group in the formula (I) is as defined in the description.

aromatic compound having fused cyclic substituent in aromatic ring and organic light-emitting diode including the same

The present invention refers to to the aromatic ring-fused ring withdrawing substituent and a compound having an same relates to organic light emitting device including, more specifically a represented by [formula A] an alkali-soluble polymer resin compound for an organic light-emitting device including organic light emitting device is characterized in that the. [Formula A] In said [formula A], X has a dementia drug; and shows strong X having substituted group, Y has a dementia drug; and shows strong formula selected from the group consisting Y1 to Y5 having one of substituted group, the n being integers, of 4 to 1, the Y5 formula to Y1 formula and X formula detailed description of the invention is described. (by machine translation)

Organosilicon compounds as adult T-cell leukemia cell proliferation inhibitors

Aggressive forms of adult T-cell leukemia (ATL) respond poorly to conventional anticancer chemotherapy, and new lead compounds are required for the development of drugs to treat this fatal disease. Recently, we developed ATL cell-selective proliferation inhibitors based on a tetrahydrotetramethylnaphthalene (TMN) skeleton 1, and here we report the design and synthesis of silicon analogs of TMN derivatives. Among them, compound 13 showed the most potent growth-inhibitory activity towards the ATL cell line S1T, though its selectivity for S1T over the non-ATL cell line MOLT-4 was only moderate. This result, as well as computational studies, suggests that sila-substitution (C/Si exchange) is useful for structure optimization of these inhibitors.

Retinoid compounds and their use

The invention relates to retinoid compounds of the formula (I): wherein V is a hydrophobic group;W is a non-polyenic linker; andX is a polar group comprising a hydrogen bond donor; or a salt thereof, and to the use of such compounds in the control of cell differentiation.